Key Events This Week
1 June: Downgrade to Strong Sell announced
2 June: Valuation metrics signal elevated risk
5 June: Week closes at Rs.0.26 (-10.34%)

Welcure Drugs & Pharmaceuticals Downgraded to Strong Sell Amidst Deteriorating Financial and Technical Metrics
2026-06-02 09:03:59Welcure Drugs & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026, reflecting deteriorating fundamentals and technical indicators. The micro-cap pharmaceutical company’s financial trend has shifted from positive to flat, valuation metrics have worsened to risky territory, and technical signals have turned bearish, signalling heightened caution for investors.
Read full news article
Welcure Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Elevated Risk Amidst Market Underperformance
2026-06-02 08:03:18Welcure Drugs & Pharmaceuticals Ltd has experienced a marked deterioration in its valuation parameters, shifting from very attractive to risky territory, as reflected in its price-to-earnings and price-to-book value ratios. This change, coupled with a significant decline in share price and underperformance relative to the Sensex, raises concerns about the stock’s price attractiveness and investment appeal within the Pharmaceuticals & Biotechnology sector.
Read full news article
Welcure Drugs Q4 FY26: Massive Loss Wipes Out Year's Gains
2026-05-30 20:20:53Welcure Drugs & Pharmaceuticals Ltd. reported a catastrophic fourth quarter for FY26, posting a net loss of ₹49.86 crores compared to a profit of ₹2.54 crores in the same quarter last year. The micro-cap pharmaceutical company's shares, trading at ₹0.29 on the NSE, have plunged 73.15% over the past year, reflecting investor alarm over the dramatic deterioration in operational performance.
Read full news article
Welcure Drugs & Pharmaceuticals Ltd is Rated Sell
2026-05-27 10:10:30Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Welcure Drugs & Pharmaceuticals Ltd is Rated Sell
2026-05-12 10:10:03Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Welcure Drugs & Pharmaceuticals Ltd is Rated Sell
2026-04-23 10:10:04Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 14 Nov 2025, reflecting a change in the company’s outlook at that time. However, all fundamentals, returns, and financial metrics discussed below are current as of 23 April 2026, providing an up-to-date view of the stock’s position in the market.
Read full news article
Welcure Drugs & Pharmaceuticals Ltd is Rated Sell
2026-04-09 10:10:18Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article






